Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study).

Authors
  • Gatlin, Marjorie
  • Jarrett, Wentworth G
  • Nwose, Oliseyenum M
Type
Published Article
Journal
Current Therapeutic Research
Publisher
Elsevier
Publication Date
Mar 01, 2004
Volume
65
Issue
2
Pages
138–148
Identifiers
DOI: 10.1016/S0011-393X(04)90028-8
PMID: 24936113
Source
Medline
Keywords
License
Unknown

Abstract

In this study of an African-American subpopulation of patients with mild to moderate essential hypertension who had uncontrolled BP while receiving amlodipine besylate monotherapy, switching from amlodipine besylate monotherapy to fixed-dose amlodipine besylate/benazepril HCl combination therapy reduced BP to a greater extent than with amlodipine besylate alone, and reduced the incidence of edema in patients who were edematous but who had controlled BP. Fixed-dose combination therapy with amlodipine besylate/benazepril HCI has the potential to improve BP control, leading to improved clinical outcomes and enhanced treatment compliance.

Report this publication

Statistics

Seen <100 times